Dermalax Implant Plus — High-Density HA Filler for Deep Contouring (2 × 1.1ml)

Dermalax Implant Plus is Across Co.’s highest-density variant — 24 mg/mL monophasic cross-linked HA + 0.3% lidocaine with the largest particle size in the Dermalax range. Engineered for deep dermis to subcutaneous placement: cheek augmentation, chin contouring, jawline definition, nose reshaping. Supplied as 2 × 1.1 mL syringes per box. 12–18 month durability with minimal migration.

Dermalax Implant Plus Filler is manufactured by Across Co. Ltd., a South Korea-based medical device and pharmaceutical company established in 2007. The product is part of the Dermalax dermal filler range, which is distributed across multiple international markets. Regulatory status: KFDA registered · CE marked · GMP certified.

Dermalax Implant Plus Filler contains 24 mg/mL of cross-linked hyaluronic acid plus 0.3% (3 mg/mL) premixed lidocaine for injection comfort. The hyaluronic acid is non-animal, produced by bacterial fermentation and cross-linked using Across Co. Ltd.’s Monophasic Cross-Linked HA (Implant Grade) technology. Phosphate-buffered saline at near-physiological pH carries the gel.

Per Across Co. Ltd.’s clinical data, Dermalax Implant Plus Filler delivers 12–18 months of correction depending on placement and patient factors. Duration depends on injection depth, dose, anatomical site, patient metabolism, and facial movement intensity. Deep dermis placement typically delivers the longer end of the duration range.

Dermalax Implant Plus Filler is engineered for deep dermis · subcutaneous placement. The standard recommended needle is 27G, supplied in the syringe blister pack. Some practitioners prefer a blunt-tip cannula of equivalent gauge for safer placement in highly vascular zones, particularly for deeper subcutaneous work.

Dermalax Implant Plus Filler regulatory status: KFDA registered · CE marked · GMP certified. The product’s KFDA registration in South Korea is the primary regulatory baseline. CE marking and other international approvals enable distribution in the EU and other regulated markets. US FDA status varies — buyers in regulated jurisdictions should verify approval scope before importation and clinical use.

Store Dermalax Implant Plus Filler between 2 °C and 25 °C in original packaging, away from direct sunlight. Do not freeze — freezing damages the HA gel structure. Shelf life is typically 24 months from the manufacturing date printed on the box when unopened. Once a syringe is opened, contents must be used immediately. Partial syringes cannot be retained for later use due to sterility risk.

No. Dermalax Implant Plus Filler uses non-animal hyaluronic acid produced by bacterial fermentation — the standard manufacturing approach for modern HA dermal fillers. The product contains no animal proteins or by-products, making it suitable for patients who avoid animal-derived medical products. The product is contraindicated in patients with severe allergies to gram-positive bacterial proteins (used in HA fermentation).

Yes — layered protocols combining different fillers are standard aesthetic practice. Dermalax Implant Plus Filler can be combined with other Korean or international HA fillers, neuromodulators (botulinum toxin), or biostimulators (PLLA, calcium hydroxylapatite) within a single session. Always wait the recommended interval between different injectable products and confirm biocompatibility per each manufacturer’s IFU.

Across Co. supplies Dermalax Implant Plus as a 2-syringe pack (2 × 1.1 mL = 2.2 mL total) because deep subcutaneous contour work — cheek augmentation, chin, jawline — typically requires more product per session than superficial wrinkle correction. The 2-syringe pack reduces the need to open a second box during a single facial sculpting session, offering improved per-treatment economics. Dermalax Plus and Deep Plus are supplied as single 1.1 mL syringes by contrast, reflecting their use in smaller-volume superficial-to-mid-dermal work.